Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Leucine-rich repeats and immunoglobulin-like domains protein 3 (LRIG3)
- Target
- LRIG3
- Molecular classification
- Transmembrane protein, Membrane protein, Other (contains leucine-rich repeats and immunoglobulin-like domains)
01
Overview
Leucine-rich repeats and immunoglobulin-like domains protein 3 (LRIG3) is a member of the LRIG family of single-pass transmembrane proteins characterized by ectodomains containing several leucine-rich repeats and immunoglobulin-like domains. LRIG3 modulates the activity of multiple receptor tyrosine kinases (including EGFR, MET, and PDGFRα) primarily in cell signaling pathways involved in cell proliferation, migration, and differentiation. Functionally, LRIG3 is implicated in both positive and negative regulation of growth factor receptor signaling, with context-dependent effects in different tissues and cancer types. Knockout studies in mice show LRIG3 is essential for normal neural crest, craniofacial, cardiac, and inner ear development. In cancer, LRIG3 is reported to modulate malignant cell behavior and may act as either a tumor suppressor or promoter. No drugs currently target LRIG3 clinically, though its expression and release as a soluble ectodomain (sLRIG3) present possible future biomarker or therapeutic applications[1][2][3].
- Other names
- LIG3LIG-3KIAA3016FLJ90440UNQ287/PRO326/PRO335leucine rich repeats and immunoglobulin like domains 3
02
Mechanism of action
no approved drugs with clearly described mechanism; research indicates involvement in negative regulation of EGFR, MET, and downstream PI3K/Akt/mTOR signaling
03
Biological functions
Regulation of growth factor receptor expression and signalingModulation of receptor tyrosine kinase pathwaysNegative regulation of EGFR signalingRegulation of neural crest cell formation and organ morphogenesisModulation of FGF and Wnt signaling pathways
04
Disease associations
Cancer (including glioma, brain stem glioma, astrocytoma, prostate cancer, cervical cancer, bladder cancer, pituitary tumors)Cardiovascular disease (cardiac hypertrophy)Craniofacial and inner ear malformations (developmental defects)
05
Safety considerations
Possible developmental impact if inhibited or silenced (craniofacial, inner ear, and cardiac defects in knockout models)Dual/contradictory role (some studies suggest tumor-suppressive, others tumor-promoting functions, particularly in cell lines)
06
Biomarkers
LRIG3 expression (proposed as a prognostic biomarker in gliomas and other cancers)Soluble LRIG3 (sLRIG3) in cell culture supernatant may be of potential biomarker interest
Beyond the preview
Go deeper on Leucine-rich repeats and immunoglobulin-like domains protein 3 (LRIG3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leucine-rich repeats and immunoglobulin-like domains protein 3 (LRIG3).